The short version
Pitocin is an oxytocin injection with obstetric indications involving medically indicated labor and postpartum bleeding. The intranasal autism trial below addresses a different route, population and purpose.
Prescription status is product-specific. A recognized ingredient name does not make every preparation equivalent.
Names you may see
Compound names, research identifiers, brand names and informal shorthand serve different purposes.
- Oxytocin
- Entry name · The name used for this encyclopedia topic.
- Pitocin
- Approved product name · Oxytocin injection with specific obstetric indications.
Similar names do not establish identical ingredients, molecular variants, product quality or interchangeable preparations. A blend nickname may describe different formulas.
Things worth checking
What should be clarified before interpreting claims?
This specific intranasal trial does not establish benefits for social bonding, sexual function, healthy adults or an oxytocin/PT-141 combination.
Identity and evidence scope · Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder ↗
Does approved oxytocin mean approved social or sexual use?
The cited label concerns obstetric injection uses. It does not establish approval or effectiveness for nasal social-enhancement products or a PT-141 blend.
Route- and indication-specific approval · DailyMed · Pitocin prescribing information ↗
Questions to bring to a clinician or pharmacist
- Which findings apply to my goal and medical history?
- Could my medicines, supplements, or other compounds change the assessment?
- What monitoring, if any, would inform a decision—and what symptoms would need evaluation?
Monitoring is individual. Normal bloodwork does not establish that a compound or preparation is safe.
Clinical research
This specific intranasal trial does not establish benefits for social bonding, sexual function, healthy adults or an oxytocin/PT-141 combination.
Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder
Summary based on: Published abstract retrieved through Europe PMC; full text not appraised
- Study design
- 24-week randomized, placebo-controlled phase 2 trial
- Who was studied
- 290 children and adolescents aged 3–17 with autism enrolled
- Route and preparation
- Intranasal study preparation
- What was compared
- Oxytocin versus placebo
- What researchers found
- No significant difference in the primary social-withdrawal outcome; secondary social and cognitive outcomes generally did not differ.
- Adverse events and stopping treatment
- Reported adverse-event frequency and severity were similar between groups.
- What this leaves unanswered
- A condition-specific trial does not establish effects in healthy adults or another route.
Research terms in everyday language ↗
This is a bounded context overview, not a completed clinical literature appraisal. The linked source has the scope stated here; related-compound findings are not evidence for this preparation.
Read findings in the context of the exact product or preparation, the people studied, and the outcome measured. These draft profiles are starting points, rather than complete systematic reviews.
Community research
Structured community reports can help identify questions worth studying. They are considered separately from controlled studies, with their limitations kept visible.
No community reports published yet.
This profile has no published community dataset. We do not infer a trend or a benefit from missing reports.
How community research will work ↗What we will document about community advice
- The advice
- What people recommend, with dated sources and the scope of the discussions examined.
- The reasoning
- Why contributors believe it helps, without treating that explanation as an established mechanism.
- The evidence
- What supports the claim, contradicts it, or has not been tested.
- The cautions
- Possible downsides, conflicting experiences, and questions for a clinician or pharmacist.
No recommendation or community consensus is established by this framework. Descriptions of how common advice is will need documented source coverage.
A closer look
- Classification
- A natural hormone with medical uses, also studied through the nose for social and behavioral conditions.
- Name variations
- Names you may see and important distinctions
- Source type
- US product label and selected research abstract
- Reference jurisdiction
- United States · approved-product context
A receptor is a structure that receives a chemical signal. An agonist activates a receptor. The mechanism section of the linked label explains the relevant pathway in greater detail.
This first design edition reserves space for study-by-study summaries, definitions, and technical references as each profile receives editorial review.
Go to the source
Study cards identify whether the summary uses an abstract, full text, or an agency assessment. Follow the linked sources for their original context.
Source reference · Checked 8 November 2026 · Opens in a new tab
For athletes: competition rules are a separate check ↗